Biotech SF: Quark

Showing posts with label Quark. Show all posts

Tuesday, May 1, 2012

Quark, Pfizer to start new mid-stage glaucoma drug trial

Quark Pharmaceuticals Inc. and Pfizer Inc. expanded a nearly 6-year-old drug-development deal to include a mid-stage trial of their RNA interference treatment in a type of glaucoma. Fremont-based Quark said Tuesday that the deal could earn it up to $165 million more in payments from Pfizer around the experimental drug, called PF-655.

Tuesday, September 27, 2011

Quark Pharma pulls IPO plans again

Quark Pharmaceuticals Inc., which develops RNA interference drugs, withdrew initial public offering plans to raise up to $20 million.
The company reportedly did not obtain favorable terms and could raise additional private funding, according to a Dow Jones VentureWire story.

Subscribe to: Posts (Atom)

Some of my favorite stories.

• "The fight of his life" (2007)

Last year Mike Homer helped raise the money for 2,000 medical research computers. Now researchers are using that equipment in an attempt to save his life.

• "For reporter, CJD is more than a story" (2007)

Seven years ago -- nearly to the day -- my mother died of Creutzfeld-Jakob Disease.

• "A son's YouTube plea for Avastin" (2010)

Josh Turnage is your typical teenager, trying to discover what he wants to do in college and with his life. But a 7-minute, 41-second YouTube video he produced about his mother's fight with breast cancer may thrust him into a debate between drug makers and the agency that regulates them.

• "New device could knock out old dialysis technology" (2011)

Shuvo Roy has all the makings for the world's first implantable artificial kidney, thanks to nanotechnology and a web of nationwide collaborations.

All he needs now is $20 million.